Rapport Therapeutics Ownership | Who Owns Rapport Therapeutics?
Rapport Therapeutics Ownership Summary
Rapport Therapeutics is owned by 10.86% institutional investors, 6.26% insiders, and 82.88% retail investors. Trv gp v is the largest institutional shareholder, holding 2.01% of RAPP shares.
RAPP Ownership Benchmark
| Type | Name | % Inst | % Insiders | % Retail |
|---|---|---|---|---|
| Stock | Rapport Therapeutics | 10.86% | 6.26% | 82.88% |
| Sector | Healthcare Stocks | 486.50% | 11.08% | -397.59% |
| Industry | Biotech Stocks | 304.14% | 11.08% | -215.23% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
| Holder | Shares | % Holding | Value |
|---|---|---|---|
| Trv gp v | 7.14M | 2.01% | $81.13M |
| Arch venture management | 3.73M | 1.05% | $42.43M |
| Cormorant asset management, lp | 2.94M | 0.83% | $33.44M |
| Capital investors | 2.60M | 0.73% | $29.59M |
| Johnson & johnson | 2.50M | 0.70% | $28.55M |
| Sofinnova investments | 2.00M | 0.56% | $22.69M |
| Blackrock funding, inc. /de | 1.22M | 0.34% | $13.86M |
| Trv gp vi | 969.22K | 0.27% | $11.02M |
| T. rowe price investment management | 613.82K | 0.17% | $6.98M |
| Baker bros. advisors lp | 550.09K | 0.16% | $6.25M |
Top Institutional Shareholders by % of Total Assets
| Holder | Shares | % Assets | Value |
|---|---|---|---|
| Trv gp v | 7.14M | 48.98% | $81.13M |
| Trv gp vi | 969.22K | 17.16% | $11.02M |
| Arch venture management | 3.73M | 14.19% | $42.43M |
| Johnson & johnson | 2.50M | 8.55% | $28.55M |
| Cormorant asset management, lp | 2.94M | 2.49% | $33.44M |
| Sofinnova investments | 2.00M | 1.39% | $22.69M |
| Sectoral asset management | 179.86K | 1.35% | $2.05M |
| Acuta capital partners | 20.00K | 0.32% | $227.40K |
| Affinity asset advisors | 199.64K | 0.31% | $2.27M |
| Logos global management lp | 208.91K | 0.26% | $2.38M |
Top Buyers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Baker bros. advisors lp | 550.09K | 0.06% | 550.09K |
| Affinity asset advisors | 199.64K | 0.31% | 199.64K |
| Sectoral asset management | 179.86K | 1.35% | 179.86K |
| Driehaus capital management | 131.34K | 0.01% | 131.34K |
| Blackrock funding, inc. /de | 1.22M | 0.00% | 51.95K |
Top Sellers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| T. rowe price investment management | 613.82K | 0.00% | -938.11K |
| Deep track capital, lp | 98.24K | 0.04% | -359.32K |
| Perceptive advisors | - | - | -311.55K |
| Jennison associates | - | - | -62.29K |
| Swiss national bank | - | - | -31.90K |
New Positions
| Holder | Shares | % Assets | Change | Value |
|---|---|---|---|---|
| Baker bros. advisors lp | 550.09K | 0.06% | 550.09K | $6.25M |
| Affinity asset advisors | 199.64K | 0.31% | 199.64K | $2.27M |
| Sectoral asset management | 179.86K | 1.35% | 179.86K | $2.05M |
| Driehaus capital management | 131.34K | 0.01% | 131.34K | $1.49M |
| Intech investment management | 11.46K | 0.00% | 11.46K | $130.32K |
Sold Out
| Holder | Change |
|---|---|
| Allworth financial lp | -15.00 |
| Nisa investment advisors | -18.00 |
| Us bancorp \de\ | -144.00 |
| Virtus etf advisers | -3.74K |
| Sandia investment management lp | -5.00K |
Institutional Ownership Trends
| Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 30, 2025 | 80 | 5.26% | 38,487,484 | 29.20% | 10 | 15.22% | 45 | -15.09% | 18 | 100.00% |
| Mar 31, 2025 | 78 | 16.42% | 38,100,888 | 4.65% | 10 | 0.10% | 52 | 36.84% | 9 | -30.77% |
| Dec 31, 2024 | 68 | 25.93% | 36,575,839 | 28.91% | 104 | 1.57% | 39 | -4.88% | 13 | 85.71% |
| Sep 30, 2024 | 54 | 54.29% | 28,374,042 | 11.02% | 81 | 1.67% | 41 | 17.14% | 7 | - |
| Jun 30, 2024 | 35 | - | 25,558,517 | - | 69 | - | 35 | - | - | - |
Recent Insider Transactions
| Date | Name | Role | Activity | Value |
|---|---|---|---|---|
| Aug 15, 2025 | Bredt David | Chief Scientific Officer | Sell | $124.31K |
| Aug 15, 2025 | Bredt David | Chief Scientific Officer | Sell | $3.16K |
| Jul 15, 2025 | Bredt David | Chief Scientific Officer | Sell | $118.96K |
| Jun 16, 2025 | Bredt David | Chief Scientific Officer | Sell | $93.52K |
| May 15, 2025 | Bredt David | Chief Scientific Officer | Sell | $81.26K |
Insider Transactions Trends
| Date | Buy | Sell |
|---|---|---|
| 2025 Q3 | - | 1 |
| 2025 Q2 | - | 3 |
| 2025 Q1 | 3 | 1 |
| 2024 Q4 | - | - |
RAPP Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools